Analysis of case fatality rate of SARS-CoV-2 infection in the Spanish Autonomous Communities between March and May 2020.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 13 04 2021
accepted: 16 11 2021
entrez: 3 12 2021
pubmed: 4 12 2021
medline: 15 12 2021
Statut: epublish

Résumé

The Spanish health system is made up of seventeen regional health systems. Through the official reporting systems, some inconsistencies and differences in case fatality rates between Autonomous Communities (CC.AA.) have been observed. Therefore the objective of this paper is to compare COVID-19 case fatality rates across the Spanish CC.AA. Observational descriptive study. The COVID-19 case fatality rate (CFR) was estimated according to the official records (CFR-PCR+), the daily mortality monitory system (MoMo) record (CFR-Mo), and the seroprevalence study ENE-COVID-19 (Estudio Nacional de sero Epidemiologia Covid-19) according to sex, age group and CC.AA. between March and June 2020. The main objective is to detect whether there are any differences in CFR between Spanish Regions using two different register systems, i. e., the official register of the Ministry of Health and the MoMo. Overall, the CFR-Mo was higher than the CFR-PCR+, 1.59% vs 0.98%. The differences in case fatality rate between both methods were significantly higher in Castilla La Mancha, Castilla y León, Cataluña, and Madrid. The difference between both methods was higher in persons over 74 years of age (CFR-PCR+ 7.5% vs 13.0% for the CFR-Mo) but without statistical significance. There was no correlation of the estimated prevalence of infection with CFR-PCR+, but there was with CFR-Mo (R2 = 0.33). Andalucía presented a SCFR below 1 with both methods, and Asturias had a SCFR higher than 1. Cataluña and Castilla La Mancha presented a SCFR greater than 1 in any scenario of SARS-CoV-2 infection calculated with SCFR-Mo. The PCR+ case fatality rate underestimates the case fatality rate of the SARS-CoV- 2 virus pandemic. It is therefore preferable to consider the MoMo case fatality rate. Significant differences have been observed in the information and registration systems and in the severity of the pandemic between the Spanish CC.AA. Although the infection prevalence correlates with case fatality rate, other factors such as age, comorbidities, and the policies adopted to address the pandemic can explain the differences observed between CC.AA.

Identifiants

pubmed: 34860848
doi: 10.1371/journal.pone.0260769
pii: PONE-D-21-12240
pmc: PMC8641878
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0260769

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

JAMA Netw Open. 2020 Aug 3;3(8):e2017533
pubmed: 32789517
Cardiovasc Pathol. 2020 Jul - Aug;47:107228
pubmed: 32375085
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Curr Oncol Rep. 2020 May 28;22(6):60
pubmed: 32462289
N Engl J Med. 2020 Aug 13;383(7):691-693
pubmed: 32427432
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32574139
J Intern Med. 2020 Oct;288(4):469-476
pubmed: 32498135
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
Med Hypotheses. 2020 Apr 24;140:109784
pubmed: 32361101
Acta Biomed. 2020 Jul 20;91(9-S):7-18
pubmed: 32701911
Semergen. 2020 Aug;46 Suppl 1:12-19
pubmed: 32709574
MMWR Morb Mortal Wkly Rep. 2020 Aug 11;69(32):1095-1099
pubmed: 32790655
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Lancet. 2020 Aug 22;396(10250):529-530
pubmed: 32771082
Curr Cardiol Rep. 2020 Apr 29;22(5):34
pubmed: 32350632
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
J Am Geriatr Soc. 2020 May;68(5):926-929
pubmed: 32255507
Lancet. 2020 Aug 22;396(10250):514-515
pubmed: 32645348
Lancet. 2020 Mar 21;395(10228):931-934
pubmed: 32164834
J Aging Soc Policy. 2020 Jul-Oct;32(4-5):380-386
pubmed: 32418475
Semergen. 2020 Aug;46 Suppl 1:35-39
pubmed: 32646731
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Lancet Public Health. 2020 Nov;5(11):e576
pubmed: 33045185
J Med Virol. 2020 Jul;92(7):919-923
pubmed: 32297983
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9696-9698
pubmed: 32300018
Biology (Basel). 2020 Jun 16;9(6):
pubmed: 32560071
QJM. 2020 Jun 1;113(6):391-392
pubmed: 32311049
Diagn Pathol. 2020 Aug 14;15(1):103
pubmed: 32799894
Euro Surveill. 2020 Jul;25(26):
pubmed: 32643601
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
BMJ. 2020 Nov 27;371:m4509
pubmed: 33246972
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
Age Ageing. 2020 Jul 1;49(4):501-515
pubmed: 32377677
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Stroke. 2020 Aug;51(8):2593-2596
pubmed: 32716828
Ann Intern Med. 2020 Nov 3;173(9):714-720
pubmed: 32698605
Brain Behav Immun. 2020 Jul;87:115-119
pubmed: 32360439
Geroscience. 2020 Apr;42(2):505-514
pubmed: 32274617
Am J Hematol. 2020 Dec;95(12):1578-1589
pubmed: 32857878

Auteurs

Martín-Sánchez V (MS)

Research Group in Gene-Environment Interactions and Health, Institute of Biomedicine (IBIOMED), University of León, León, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Calderón-Montero A (CM)

Doctor Pedro Laín Entralgo Health Center, Madrid Health Service (SERMAS), Alcorcón, Madrid, Spain.

Barquilla-García A (BG)

Trujillo Health Center, Extremadura Health Service, Cáceres, Spain.

Vitelli-Storelli F (VS)

Research Group in Gene-Environment Interactions and Health, Institute of Biomedicine (IBIOMED), University of León, León, Spain.

Segura-Fragoso A (SF)

Health Science Department, Castilla La Mancha University, Talavera de la Reina, Toledo, Spain.

Olmo-Quintana V (OQ)

Management Pharmacy Service Primary Health Care, Vicepresident of Ethical Committee Research with Medicine Hospital Dr. Negrín Gran Canaria Las Palmas (CEI/CEIm) Canary Health Service, Las Palmas, Spain.

Serrano-Cumplido A (SC)

Family and Community Medicine, Getxo, Bizkaia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH